Litcius/Paper detail

A case of thoracic <scp> <i>SMARCA4</i> ‐Deficient </scp> undifferentiated tumor successfully treated with combination <scp>Ipilimumab–Nivolumab</scp>

Yoshio Nakano, Daisuke Sekinada, Yusuke Kuze, Norio Okamoto, Iwao Gohma, Yumiko Yasuhara

2022Clinical Case Reports11 citationsDOIOpen Access PDF

Abstract

Abstract Thoracic SMARCA4 ‐deficient undifferentiated tumors are rare, with poor prognosis. A 73‐year‐old man presented to our hospital with dyspnea. Computed tomography‐guided biopsy revealed a SMARCA4 ‐deficient undifferentiated tumor. The patient was treated with combination ipilimumab‐nivolumab. The tumor reduced in size after two courses.

Topics & Concepts

IpilimumabNivolumabMedicineSMARCA4BiopsyInternal medicineRadiologyImmunotherapyCancerChromatin remodelingBiologyDNAGeneticsChromatinChromatin Remodeling and CancerPeptidase Inhibition and AnalysisNeuroendocrine Tumor Research Advances
A case of thoracic <scp> <i>SMARCA4</i> ‐Deficient </scp> undifferentiated tumor successfully treated with combination <scp>Ipilimumab–Nivolumab</scp> | Litcius